Advances in Chronic Kidney Disease
Volume 11, Issue 3 , Pages 261-273 , July 2004

Optimal dialysis for the end-stage renal disease patient with cardiovascular disease

  • Francis Dumler

      Affiliations

    • Department of Medicine, Divisions of Nephrology, Cardiology, and Preventive Medicine, William Beaumont Hospital, Royal Oak, MI, USA
    • Corresponding Author InformationAddress correspondence to Francis Dumler, MD, Division of Nephrology, 3601 West Thirteen Mile Road, Suite 644, Royal Oak, MI 48073 USA
    • ,
  • Peter A McCullough

      Affiliations

    • Department of Medicine, Divisions of Nephrology, Cardiology, and Preventive Medicine, William Beaumont Hospital, Royal Oak, MI, USA

References 

  1. McCullough PA. Acute coronary syndromes in patients with renal failure. Curr Cardiol Rep. 2003;5:266–270
  2. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci. 2003;4:163–167
  3. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients (Left ventricular hypertrophy, ischemic heart disease, and cardiac failure). Semin Dial. 2003;16:111–117
  4. Kendrick E. CVD and the renal transplant recipient. Am J Kidney Dis. 2001;38(suppl):S36–S43
  5. Collins AJ, Li S, Ma JZ, et al.  CVD in end-stage renal disease patients. Am J Kidney Dis. 2001;38(suppl):S26–S29
  6. Amann K, Tyralla K, Gross ML, et al.  Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol. 2003;60(suppl):S13–S21
  7. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int. 2003;85(suppl):S105–S110
  8. Prichard S. Risk factors for coronary artery disease in patients with renal failure. Am J Med Sci. 2003;325:309–313
  9. Reslerova M, Moe SM. Vascular calcification in dialysis patients (Pathogenesis and consequences). Am J Kidney Dis. 2003;41(suppl):S96–S99
  10. Paparello J, Kshirsagar A, Batlle D. Comorbidity and cardiovascular risk factors in patients with CKD. Semin Nephrol. 2002;22: 494–450
  11. Ponticelli C, Villa M. Role of anaemia in cardiovascular mortality and morbidity in transplant patients. Nephrol Dial Transplant. 2002;17:41–46
  12. Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant. 2002;17:336–339
  13. Bayes B, Pastor MC, Bonal J, et al.  Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant. 2003;18:6–12
  14. De Santo NG, Cirillo M, Perna A, et al.  The heart in uremia (Role of hypertension, hypotension, and sleep apnea). Am J Kidney Dis. 2001;38(suppl):S38–S46
  15. U.S. Renal Data System: USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003;
  16. Caruana RJ. First-use reactions (A potential hazard for referral centers). Int J Artif Organs. 1989;12(11):688–691
  17. Daugirdas JT, Ing TS. First-use reactions during hemodialysis (A definition of subtypes). Kidney Int. 1988;24(suppl):S37–S43
  18. Lemke HD, Heidland A, Schaefer RM. Hypersensitivity reactions during haemodialysis (Role of complement fragments and ethylene oxide antibodies). Nephrol Dial Transplant. 1990;5:264–269
  19. Nicholls AJ. Hypersensitivity to hemodialysis (The United Kingdom experience). Artif Organs. 1987;11:87–89
  20. Bommer J, Ritz E. Ethylene oxide (ETO) as a major cause of anaphylactoid reactions in dialysis (a review). Artif Organs. 1987;11:111–117
  21. Hakim RM, Breillatt J, Lazarus JM, et al.  Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med. 1984;311:878–882
  22. Schulman G, Hakim R, Arias R, et al.  Bradykinin generation by dialysis membranes (Possible role in anaphylactic reaction). J Am Soc Nephrol. 1993;3:1563–1569
  23. Pegues DA, Beck-Sague CM, Woollen SW, et al.  Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int. 1992;42:1232–1237
  24. Brunet P, Jaber K, Berland Y, et al.  Anaphylactoid reactions during hemodialysis and hemofiltration (Role of associating AN69 membrane and angiotensin I-converting enzyme inhibitors). Am J Kidney Dis. 1992;19:444–447
  25. Parnes EL, Shapiro WB. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int. 1991;40:1148–1152
  26. Tielemans C, Madhoun P, Lenaers M. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int. 1990;38:982–984
  27. Wiegmann TB, MacDougall ML, Diederich DA. Dialysis leukopenia, hypoxemia, and anaphylatoxin formation (Effect of membrane, bath, and citrate anticoagulation). Am J Kidney Dis. 1988;11:418–424
  28. Abu-Hamdan DK, Desai SG, Mahajan SK, et al.  Hypoxemia during hemodialysis using acetate versus bicarbonate dialysate. Am J Nephrol. 1984;4:248–253
  29. Hakim RM, Lowrie EG. Hemodialysis-associated neutropenia and hypoxemia (The effect of dialyzer membrane materials). Nephron. 1982;32:32–39
  30. Dumler F. Membrane biocompatibility (Clinical significance and therapeutic implications). Int J Artif Organs. 1985;8:257–262
  31. Daugirdas JT. Pathophysiology of dialysis hypotension (An update). Am J Kidney Dis. 2001;38(suppl):S11–S17
  32. Barth C, Boer W, Garzoni D, et al.  Characteristics of hypotension-prone haemodialysis patients (Is there a critical relative blood volume?). Nephrol Dial Transplant. 2003;18:353–360
  33. Andrulli S, Colzani S, Mascia F, et al.  The role of blood volume reduction in the genesis of intradialytic hypotension. Am J Kidney Dis. 2002;40:1244–1254
  34. Prakash S, Reddan D, Heidenheim AP, et al.  Central, peripheral, and other blood volume changes during hemodialysis. ASAIO J. 2002;48:379–382
  35. Sherman RA. Intradialytic hypotension (An overview of recent, unresolved and overlooked issues). Semin Dial. 2002;15:141–143
  36. Leypoldt JK, Cheung AK, Delmez JA. Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int. 2002;61:266–275
  37. Bradley JR, Evans DB, Gore SM, et al.  Is dialysis hypotension caused by an abnormality of venous tone?. Br Med J. 1988;296:1634–1637
  38. Kooman JP, Gladziwa U, Bocker G, et al.  Role of the venous system in hemodynamics during ultrafiltration and bicarbonate dialysis. Kidney Int. 1992;42:718–726
  39. Chang MH, Chou KJ. The role of autonomic neuropathy in the genesis of intradialytic hypotension. Am J Nephrol. 2001;21:357–361
  40. Henrich WL. Hemodynamic instability during hemodialysis. Kidney Int. 1986;30:605
  41. Converse RL, Jacobsen TN, Jost CM, et al.  Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest. 1992;90:1657–1665
  42. Zhu F, Schneditz D, Wang E, et al.  Validation of changes in extracellular volume measured during hemodialysis using a segmental bioimpedance technique. ASAIO J. 1998;44:541–545
  43. Dumler F, Kilates C. Use of bioelectrical impedance techniques for monitoring nutritional status in patients on maintenance dialysis. J Ren Nutr. 2000;10:116–124
  44. Cox-Reijven PL, Kooman JP, Soeters PB, et al.  Role of bioimpedance spectroscopy in assessment of body water compartments in hemodialysis patients. Am J Kidney Dis. 2001;38:832–838
  45. Kushner RF, Roxe DM. Bipedal bioelectrical impedance analysis reproducibly estimates total body water in hemodialysis patients. Am J Kidney Dis. 2002;39:154–158
  46. Chamney PW, Kramer M, Rode C, et al.  A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedance. Kidney Int. 2002;6:12250–12258
  47. Konings CJ, Kooman JP, Schonck M, et al.  Assessment of fluid status in peritoneal dialysis patients. Perit Dial Int. 2002;22:683–692
  48. Zhu F, Schneditz D, Kaufman AM, et al.  Estimation of body fluid changes during peritoneal dialysis by segmental bioimpedance analysis. Kidney Int. 2000;57:299–306
  49. Piccoli A, Rossi B, Pillon L, et al.  A new method for monitoring body fluid variation by bioimpedance analysis (The RXc graph). Kidney Int. 1994;46:534–539
  50. Piccoli A, Pillon L, Dumler F. Impedance vector distribution by sex, race, body mass index, and age in the United States (Standard reference intervals as bivariate Z scores). Nutrition. 2002;18:153–167
  51. Maisel AS, Krishnaswamy P, Nowak RM, et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  52. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol. 2003;285:F167–F177
  53. Kanozawa K, Shimosawa T, Nagasawa R, et al.  Mature form of adrenomedullin is a useful marker to evaluate blood volume in hemodialysis patients. Am J Kidney Dis. 2002;40:794–801
  54. Cataliotti A, Malatino LS, Jougasaki M, et al.  Circulating natriuretic peptide concentrations in patients with end-stage renal disease (Role of brain natriuretic peptide as a biomarker for ventricular remodeling). Mayo Clin Proc. 2001;76:1111–1119
  55. Metry G, Hall C, Wikstrom B, et al.  Fluid balance in patients with chronic renal failure assessed with N-terminal proatrial natriuretic peptide, atrial natriuretic peptide and ultrasonography. Acta Physiol Scand. 2001;171:117–122
  56. Franz M, Woloszczuk W, Horl WH. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int. 2000;58:374–383
  57. Odar-Cederlof I, Ericsson F, Theodorsson E, et al.  Neuropeptide-Y and atrial natriuretic peptide as prognostic markers in patients on hemodialysis. ASAIO J. 2003;49:74–80
  58. Zoccali C, Mallamaci F, Benedetto FA, et al.  Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12:1508–1515
  59. Nishikimi T, Futoo Y, Tamano K, et al.  Plasma brain natriuretic peptide levels in chronic hemodialysis patients (Influence of coronary artery disease). Am J Kidney Dis. 2001;37:201–208
  60. Mallamaci F, Zoccali C, Tripepi G, et al.  The Cardiovascular Risk Extended Evaluation. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001;59:1559–1566
  61. McIntyre CW, Lambie SH, Fluck RJ. Biofeedback controlled hemodialysis (BF-HD) reduces symptoms and increases both hemodynamic tolerability and dialysis adequacy in non-hypotensive prone stable patients. Clin Nephrol. 2003;60:105–112
  62. Santoro A, Mancini E, Basile C, et al.  Blood volume controlled hemodialysis in hypotensive-prone patients (A randomized, multicenter, controlled trial). Kidney Int. 2002;62:1043–1045
  63. Song JH, Lee SW, Suh CK, et al.  Time-averaged concentration of dialysate sodium relates with sodium load and interdialytic weight gain during sodium-profiling hemodialysis. AM J Kidney Dis. 2002;40:291–301
  64. Monger MA, Ateshkadi A, Cheung AK, et al.  Cardiopulmonary events during hemodialysis (Effects of dialysis membranes and dialysate buffers). Am J Kidney Dis. 2000;36:130–139
  65. Verzetti G, Navino C, Bolzani R, et al.  Acetate-free biofiltration versus bicarbonate haemodialysis in the treatment of patients with diabetic nephropathy (A cross-over multicentric study). Nephrol Dial Transplant. 1998;13:955–961
  66. Donauer J, Schweiger C, Rumberger B, et al.  Reduction of hypotensive effects during online-haemodiafiltration and low tempaerature haemodialysis. Nephrol Dial Transplant. 2003;18:1616–1622
  67. Hoeben H, Abu-Alfa AK, Mahnensmith R. Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. Am J kidney Dis. 2002;39:102–107
  68. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201–208
  69. Cice G, Ferrara L, D’Andrea A, et al.  Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy (a prospective, placebo-controlled trial). J Am Coll Cardiol. 2003;41:1438–1444
  70. Alappan R, Cruz D, Abu-Alfa AK, et al.  Treatment of severe intradialytic hypotension with the addition of high dialysate calcium concentration to midodrine and/or cool dialysate. Am J Kidney Dis. 2001;37:294
  71. Levin A. Anemia and left ventricular hypertrophy in CKD populations (A review of the current state of knowledge). Kidney Int. 2002;80(suppl):35–38
  72. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis. 2002;406:1202–1210
  73. Gomez JM, Carrera F. What should the optimal target hemoglobin be?. Kidney Int. 2002;80(suppl):39–43
  74. Ahmad S, Robertson HT, Golper TA, et al.  Multicenter trial of l-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int. 1990;38(5):912–918
  75. Emili S, Black NA, Paul RV, et al.  A protocol-based treatment for intradialytic hypotension in hospitalized hemodialysis patients. Am J kidney Dis. 1999;33:1107–1114
  76. Cruz DN, Mahnensmith RL, Brickel HM, et al.  Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. Am J Kidney Dis. 1999;33:920–926
  77. Donauer J, Kolblin D, Bek M, et al.  Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects. Am J Kidney Dis. 2000;36:115–123
  78. Dheenan S, Heinrich WL. Preventing dialysis hypotension (A comparison of usual protective maneuvers). Kidney Int. 2001;59:1175–1181
  79. Stiller S, Bonnie-Schorn E, Grassmann A, et al.  A critical review of sodium profiling for hemodialysis. Semin Dial. 2001;14:337–347
  80. Perazella MA. Pharmacologic options available to treat symptomatic intradialytic hypotension. Am J Kidney Dis. 2001;38(suppl):S26–S36
  81. Nette RW, Krepel HP, van den Meiracker AH, et al.  Specific effect of the infusion of glucose on blood volume during haemodialysis. Nephrol Dial Transplant. 2002;17:1275–1280
  82. Begin V, Deziel C, Madore F. Biofeedback regulation of ultrafiltration and dialysate conductivity for the prevention of hypotension during hemodialysis. ASAIO J. 2002;48:312–315
  83. Bellinghieri G, Santoro D, Calvini M, et al.  Carnitine and hemodialysis. Am J Kidney Dis. 2003;41(suppl):S111–S122
  84. Nakamura S, Uzu T, Inenaga T, et al.  Prediction of coronary artery disease and cardiac events using electrocardiographic changes during hemodialysis. Am J Kidney Dis. 2000;36(3):592–599
  85. Freda BJ, Tang WH, Van Lente F, et al.  Cardiac troponins in renal insufficiency (Review and clinical implications). J Am Coll Cardiol. 2002;40(12):2065–2071
  86. McCullough PA, Nowak RM, Foreback C, et al.  Performance of multiple cardiac biomarkers measured in the emergency department in patients with chronic kidney disease and chest pain. Acad Emerg Med. 2002;9:1389–1396
  87. Apple FS, Murakami MM, Pearce LA, et al.  Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106(23):2941–2945
  88. Jassal SBV, Coulshed SJ, Douglas JF, et al.  Autonomic neuropathy predisposing to arrhythmias in hemodialysis patients. Am J Kidney Dis. 1997;30:219–223
  89. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 1999;55:1553–1559
  90. Barnas MG, Boer WH, Koomans HA. Hemodynamic patterns and spectral analysis of heart rate variability during dialysis hypotension. J Am Soc Nephrol. 1999;10:2577–2584
  91. Vazquez E, Sanchez-Perales C, Lozano C, et al.  Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol. 2003;92:868–871
  92. Herzog CA. Cardiac arrest in dialysis patients (Approaches to alter an abysmal outcome). Kidney Int. 2003;84(suppl):S197–S200
  93. Eknoyan G, Beck GJ, Cheung AK, et al.  Hemodialysis (HEMO) Study Group   Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  94. Rahman M, Dixit A, Donley V, et al.  Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis. 1999;33:498–506
  95. Sang GL, Kovithavongs C, Ulan R, et al.  Sodium ramping in hemodialysis (A study of beneficial and adverse effects). Am J Kidney Dis. 1997;29:669–677
  96. Dumler F, Levin NW. Leukopenia and hypoxemia (Unrelated effects of hemodialysis). Arch Intern Med. 1979;139:1103–1106
  97. Hakim RM, Lowrie EG. Hemodialysis-associated neutropenia and hypoxemia (The effect of dialyzer membrane materials). Nephron. 1982;32:32–39
  98. Abu-Hamdan DK, Desai SG, Mahajan SK, et al.  Hypoxemia during hemodialysis using acetate versus bicarbonate dialysate. Am J Nephrol. 1984;4:248–253
  99. Francos GC, Besarab A, Burke F, et al.  Dialysis-induced hypoxemia (Membrane dependent and membrane independent causes). Am J Kidney Dis. 1985;5:191–198
  100. Oh MS, Uribarri J, Del Monte ML, et al.  A mechanism of hypoxemia during hemodialysis. Consumption of CO2 in metabolism of acetate. Am J Nephrol. 1985;5:366–371
  101. Ross EA, Tashkin D, Chenoweth D, et al.  Pulmonary leukosequestration without hypoxemia during hemodialysis. Int J Artif Organs. 1987;10:367–374
  102. Wiegmann TB, MacDougall ML, Diederich DA. Dialysis leukopenia, hypoxemia, and anaphylatoxin formation (effect of membrane, bath, and citrate anticoagulation). Am J Kidney Dis. 1988;11:418–424
  103. Soliani F, Davoli V, Franco V, et al.  Intradialytic changes of the oxyhaemoglobin dissociation curve during acetate and bicarbonate haemodialysis (Possible interactions with haemodialysis associated hypoxemia). Nephrol Dial Transplant. 1990;5(suppl 1):119–121
  104. Ganss R, Aarseth BP, Nordby G. Prevention of hemodialysis associated hypoxemia by use of low concentration bicarbonate dialysate. ASAIO J. 1992;38:820–822
  105. Wang AY, Woo J, Wang M, et al.  Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol. 2001;12:1927–1936
  106. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome—the heart of the matter. Nephrol Dial Transplant. 2002;17(suppl 11):28–31
  107. Raggi P, Ali O. Phosphorus restriction and control of coronary calcification as assessed by electron beam tomography. Curr Opin Nephrol Hypertens. 2002;11:391–395
  108. Raggi P. Effects of excess calcium load on the cardiovascular system measured by electron beam tomography in end-stage renal disease. Nephrol Dial Transplant. 2002;17:332–335
  109. Raggi P, Boulay A, Chasan-Taber S, et al.  Cardiac calcification in adult hemodialysis patients (A link between end-stage renal disease and CVD?). J Am Coll Cardiol. 2002;39:695–701
  110. Wang AY, Wang M, Woo J, et al.  Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients (A prospective study). J Am Soc Nephrol. 2003;14:159–168
  111. Di Leo C, Gallieni M, Bestetti A, et al.  Cardiac and pulmonary calcification in a hemodialysis patient (partial regression 4 years after parathyroidectomy). Clin Nephrol. 2003;59:59–63
  112. Ummana E, Ahmed W, Alpert MA. Valvular and perivalvular abnormalities in end-stage renal disease. Am J Med Sci. 2003;325:237–242
  113. Chertow GM, Raggi P, McCarthy JT, et al.  The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol. 2003;2:307–314
  114. Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis. 2004;13:134–141
  115. McCullough PA, Sandberg KR, Yanez J: Determinants of vascular calcification in patients with chronic kidney disease and end-stage renal disease: A systematic review. J Nephrol (in press)
  116. Chan CT, Floras JS, Miller JA, et al.  Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002;61:2235–2239
  117. Klarenbach S, Heidenheim AP, Leitch R, et al.  Daily/Nocturnal Dialysis Study Group   Reduced requirement for erythropoietin with quotidian hemodialysis therapy. ASAIO J. 2002;48:57–61
  118. Chan C, Floras JS, Miller JA, et al.  Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant. 2002;17:1518–1521
  119. Andre MB, Rembold SM, Pereira CM, et al.  Prospective evaluation of an in-center daily hemodialysis program (Results of two years of treatment). Am J Nephrol. 2002;22:473–479
  120. Lindsay RM, Alhejaili F, Nesrallah G, et al.  Calcium and phosphate balance with quotidian hemodialysis. Am J Kidney Dis. 2003;42(1 suppl):24–29
  121. Chan CT, Mardirossian S, Faratro R, et al.  Improvement in lower-extremity peripheral arterial disease by nocturnal hemodialysis. Am J Kidney Dis. 2003;4:225–229
  122. Ganesh SK, Hulbert-Shearon T, Port FK, et al.  Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol. 2003;14:415–424
  123. United States Renal Data System: USRDS 2003 Annual Data Report. US Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis. 2003;41(suppl 2):S1–S226

PII: S1548-5595(04)00073-4

doi: 10.1053/j.arrt.2004.04.004

Advances in Chronic Kidney Disease
Volume 11, Issue 3 , Pages 261-273 , July 2004

Article Tools

* Image Usage & Resolution